ofloxacin has been researched along with Sepsis in 38 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 9.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| " To this day, no other case of prostatic abscess due to this strain but susceptible to methicillin has been described." | 7.80 | Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. ( Barraud, O; Brakbi, Y; Cypierre, A; Dubos, M; Fedou, AL; François, B; Fredon, F; Laurent, F, 2014) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 7.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "Fluoroquinolones are the most commonly used prophylactic antimicrobials for ultrasound-guided transrectal prostate biopsy due to their broad pathogen spectrum, pharmacokinetics, bioavailability and ease of oral administration." | 6.44 | Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. ( Fujisawa, M; Miura, T; Nakano, Y; Shigemura, K; Takenaka, A; Tanaka, K, 2008) |
| "These results suggest that tandem cycles of concurrent 96-h infusions of dexrazoxane and high-dose doxorubicin can be administered with minimal cardiac toxicity, and have activity in patients with recurrent sarcomas." | 5.11 | Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. ( Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y, 2004) |
| "An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis." | 5.09 | Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. ( Geddes, A; Härkönen, M; Jacobs, F; Nowotny, I; Schonwald, S; Thaler, M, 1999) |
| "To compare the cost-effectiveness of sequential intravenous-to-oral ofloxacin versus intravenous-to-oral standard switch therapy for the treatment of patients with sepsis who are hospitalized with bacterial infections." | 5.08 | Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. ( Paladino, JA; Partsch, DJ, 1997) |
| " To this day, no other case of prostatic abscess due to this strain but susceptible to methicillin has been described." | 3.80 | Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. ( Barraud, O; Brakbi, Y; Cypierre, A; Dubos, M; Fedou, AL; François, B; Fredon, F; Laurent, F, 2014) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 3.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "In a fibrin-clot model of sepsis, developed in mice, treatment with the antibiotics ceftazidime (Cfz) and ofloxacin (Ofl) caused significant (p < 0." | 3.73 | Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis. ( Bramhne, HG; Chhibber, S; Sharma, S; Toky, V, 2005) |
| " These differences can pose challenges in developing appropriate dosing guidelines." | 2.72 | Do intensive care patients need an individualized dosing regimen for levofloxacin? ( Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR, 2006) |
| " Dosage adjustment was made for patients in renal failure." | 2.67 | Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. ( Beaucaire, G; Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1990) |
| "Ofloxacin was administered at a dose of 200 mg every 12 hours for a mean duration of ten days." | 2.66 | [Efficacy of injectable ofloxacin in treating septicemia. Multicenter study]. ( Doco-Lecompte, T; Modaï, J, 1989) |
| "Fluoroquinolones are the most commonly used prophylactic antimicrobials for ultrasound-guided transrectal prostate biopsy due to their broad pathogen spectrum, pharmacokinetics, bioavailability and ease of oral administration." | 2.44 | Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. ( Fujisawa, M; Miura, T; Nakano, Y; Shigemura, K; Takenaka, A; Tanaka, K, 2008) |
| "Septic pulmonary embolism (SPE) is an uncommon, but life-threatening event that is usually associated with extrapulmonary infections." | 1.37 | Tsukamurella tyrosinosolvens and Rhizobium radiobacter sepsis presenting with septic pulmonary emboli. ( Calista, F; Fadda, G; Fiori, B; Mignogna, S; Romano, L; Sali, M; Spanu, T; Zappacosta, B, 2011) |
| "Sepsis was diagnosed in 17 patients (3." | 1.37 | Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. ( Akduman, B; Akduman, D; Ayoğlu, F; Erol, B; Mungan, NA; Tokgöz, H; Türker, T, 2011) |
| "Treatment with levofloxacin could not prevent abortion." | 1.33 | An unusual cause of sepsis during pregnancy: recognizing infection with chlamydophila abortus. ( Brezinka, C; Gritsch, W; Hotzel, H; Ploner, F; Tauber, R; Walder, G; Würzner, R, 2005) |
| " In these strains, levofloxacin ED(50)s were 2- to 10-fold lower than the ED(50)/MIC ratios in the other strains and 90% E(max) AUC/MIC ratios were 2- to 4-fold lower than those predicted from pharmacodynamic modeling of efficacy against other strains." | 1.33 | Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? ( Cho, D; Corcoran, E; Dudley, MN; Griffith, DC; Lee, A; Lofland, D; Lomovskaya, O, 2006) |
| " In addition to standard pharmacokinetic parameters, the total dialysate concentration of both drugs was measured using a technically simple single-pass batch dialysis system for EDD." | 1.33 | Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. ( Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S, 2006) |
| "The first case of septicemia due to Yersinia pseudotuberculosis in an HIV-infected person was reported." | 1.32 | Short Communication: Yersinia pseudotuberculosis septicemia in an HIV-infected patient failed HAART. ( Alba, L; Antinori, A; Boumis, E; Festa, A; Marconi, P; Paglia, MG; Pucillo, LP; Visca, P, 2004) |
| "Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls." | 1.28 | Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.26) | 18.7374 |
| 1990's | 8 (21.05) | 18.2507 |
| 2000's | 21 (55.26) | 29.6817 |
| 2010's | 7 (18.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubos, M | 1 |
| Barraud, O | 1 |
| Fedou, AL | 1 |
| Fredon, F | 1 |
| Laurent, F | 1 |
| Brakbi, Y | 1 |
| Cypierre, A | 1 |
| François, B | 1 |
| Green, O | 1 |
| Murray, P | 1 |
| Gea-Banacloche, JC | 1 |
| Sarullo, FM | 1 |
| Americo, L | 1 |
| Accardo, S | 1 |
| Cicero, S | 1 |
| Schicchi, R | 1 |
| Schirò, M | 1 |
| Castello, A | 1 |
| Gupta, A | 2 |
| Khaira, A | 1 |
| Bhalla, AK | 1 |
| Rana, DS | 1 |
| Romano, L | 1 |
| Spanu, T | 1 |
| Calista, F | 1 |
| Zappacosta, B | 1 |
| Mignogna, S | 1 |
| Sali, M | 1 |
| Fiori, B | 1 |
| Fadda, G | 1 |
| Akduman, B | 1 |
| Akduman, D | 1 |
| Tokgöz, H | 1 |
| Erol, B | 1 |
| Türker, T | 1 |
| Ayoğlu, F | 1 |
| Mungan, NA | 1 |
| Loeb, S | 1 |
| Manecksha, RP | 1 |
| Nason, GJ | 1 |
| Cullen, IM | 1 |
| Fennell, JP | 1 |
| McEvoy, E | 1 |
| McDermott, T | 1 |
| Flynn, RJ | 1 |
| Grainger, R | 1 |
| Thornhill, JA | 1 |
| Parra-Riffo, H | 1 |
| Lemus-Peñaloza, J | 1 |
| Georgescu, V | 1 |
| Lespessailles, E | 1 |
| Martin, L | 1 |
| Poisson, DM | 1 |
| Estève, E | 1 |
| Zeitlinger, MA | 1 |
| Dehghanyar, P | 1 |
| Mayer, BX | 1 |
| Schenk, BS | 1 |
| Neckel, U | 1 |
| Heinz, G | 1 |
| Georgopoulos, A | 1 |
| Müller, M | 1 |
| Joukhadar, C | 1 |
| Nakayama, K | 1 |
| Ishida, Y | 1 |
| Ohtsuka, M | 1 |
| Kawato, H | 1 |
| Yoshida, K | 2 |
| Yokomizo, Y | 1 |
| Ohta, T | 1 |
| Hoshino, K | 2 |
| Otani, T | 1 |
| Kurosaka, Y | 1 |
| Ishida, H | 1 |
| Lee, VJ | 1 |
| Renau, TE | 1 |
| Watkins, WJ | 1 |
| Candel, FJ | 1 |
| Roca-Arbonés, V | 1 |
| Núñez, MJ | 1 |
| Arroyo, C | 1 |
| Valdivia, A | 1 |
| Téllez, MJ | 1 |
| Picazo, JJ | 1 |
| Chow, WA | 1 |
| Synold, TW | 1 |
| Tetef, ML | 1 |
| Longmate, J | 1 |
| Frankel, P | 1 |
| Lawrence, J | 1 |
| Al-Khadimi, Z | 1 |
| Leong, L | 1 |
| Lim, D | 1 |
| Margolin, K | 1 |
| Morgan, RJ | 1 |
| Raschko, J | 1 |
| Shibata, S | 1 |
| Somlo, G | 1 |
| Twardowski, P | 1 |
| Yen, Y | 1 |
| Doroshow, JH | 1 |
| Antinori, A | 1 |
| Paglia, MG | 1 |
| Marconi, P | 1 |
| Festa, A | 1 |
| Alba, L | 1 |
| Boumis, E | 1 |
| Pucillo, LP | 1 |
| Visca, P | 1 |
| Bauhofer, A | 1 |
| Celik, I | 1 |
| Plaul, U | 1 |
| Wulf, H | 1 |
| Torossian, A | 1 |
| Alkorta, M | 1 |
| Giménez, MJ | 1 |
| Vicente, D | 1 |
| Aguilar, L | 1 |
| Pérez-Trallero, E | 1 |
| Toky, V | 1 |
| Sharma, S | 1 |
| Bramhne, HG | 1 |
| Chhibber, S | 1 |
| Walder, G | 1 |
| Hotzel, H | 1 |
| Brezinka, C | 1 |
| Gritsch, W | 1 |
| Tauber, R | 1 |
| Würzner, R | 1 |
| Ploner, F | 1 |
| Ruotsalainen, E | 1 |
| Järvinen, A | 1 |
| Koivula, I | 1 |
| Kauma, H | 1 |
| Rintala, E | 1 |
| Lumio, J | 1 |
| Kotilainen, P | 1 |
| Vaara, M | 1 |
| Nikoskelainen, J | 1 |
| Valtonen, V | 1 |
| Griffith, DC | 1 |
| Corcoran, E | 1 |
| Lofland, D | 1 |
| Lee, A | 1 |
| Cho, D | 1 |
| Lomovskaya, O | 1 |
| Dudley, MN | 1 |
| Tayab, ZR | 1 |
| Hochhaus, G | 1 |
| Kaufmann, S | 1 |
| Jäger, D | 1 |
| Barth, J | 1 |
| Ozkan, S | 1 |
| Akay, T | 1 |
| Randhawa, VS | 1 |
| Kumar, A | 1 |
| Saili, A | 1 |
| Datta, V | 1 |
| Agrawal, C | 1 |
| Mehta, G | 1 |
| Czock, D | 1 |
| Hüsig-Linde, C | 1 |
| Langhoff, A | 1 |
| Schöpke, T | 1 |
| Hafer, C | 1 |
| de Groot, K | 1 |
| Swoboda, S | 1 |
| Kuse, E | 1 |
| Haller, H | 1 |
| Fliser, D | 1 |
| Keller, F | 1 |
| Kielstein, JT | 1 |
| Miura, T | 1 |
| Tanaka, K | 1 |
| Shigemura, K | 1 |
| Nakano, Y | 1 |
| Takenaka, A | 1 |
| Fujisawa, M | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| Partsch, DJ | 1 |
| Paladino, JA | 1 |
| Geddes, A | 1 |
| Thaler, M | 1 |
| Schonwald, S | 1 |
| Härkönen, M | 1 |
| Jacobs, F | 1 |
| Nowotny, I | 1 |
| Lin, FY | 1 |
| Azimi, PH | 1 |
| Weisman, LE | 1 |
| Philips, JB | 1 |
| Regan, J | 1 |
| Clark, P | 1 |
| Rhoads, GG | 1 |
| Clemens, J | 1 |
| Troendle, J | 1 |
| Pratt, E | 1 |
| Brenner, RA | 1 |
| Gill, V | 1 |
| Inoue, M | 1 |
| Kuga, A | 1 |
| Kaieda, S | 1 |
| Hosaka, M | 1 |
| Kitasato, H | 1 |
| Sato, Y | 1 |
| Okamoto, R | 1 |
| Eda, T | 1 |
| Seto, I | 1 |
| Brook, I | 2 |
| Ledney, GD | 2 |
| Azoulay-Dupuis, E | 1 |
| Bedos, JP | 1 |
| Vallée, E | 1 |
| Hardy, DJ | 1 |
| Swanson, RN | 1 |
| Pocidalo, JJ | 1 |
| Lode, H | 1 |
| Wiley, E | 1 |
| Olschewski, P | 1 |
| Sievers, H | 1 |
| Wintermantel, M | 1 |
| Baetz, R | 1 |
| Lebahn, K | 1 |
| Reinke, M | 1 |
| Wagner, J | 1 |
| Borner, K | 1 |
| Mouton, Y | 1 |
| Leroy, O | 1 |
| Beuscart, C | 1 |
| Sivery, B | 1 |
| Senneville, E | 1 |
| Chidiac, C | 1 |
| Beaucaire, G | 1 |
| Vincent du Laurier, M | 1 |
| Doco-Lecompte, T | 1 |
| Modaï, J | 1 |
| Umeki, S | 1 |
| Okamoto, Y | 1 |
| Hisamoto, N | 1 |
| Hara, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00548002] | 430 participants (Actual) | Observational | 1999-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ofloxacin and Sepsis
| Article | Year |
|---|---|
Severe levofloxacin-induced hypoglycaemia: a case report and literature review.
Topics: Aged; Anti-Bacterial Agents; Catheter-Related Infections; Drug Therapy, Combination; Enterococcus; G | 2012 |
Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2008 |
8 trials available for ofloxacin and Sepsis
| Article | Year |
|---|---|
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule | 2004 |
Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Chi-Square Distribution; Drug Therapy, Combination; | 2006 |
Do intensive care patients need an individualized dosing regimen for levofloxacin?
Topics: Anti-Bacterial Agents; Critical Illness; Female; Humans; Intensive Care Units; Levofloxacin; Male; M | 2006 |
Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Cost-Benefit Analysis; Delivery of Health C | 1997 |
Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteremia; Cilastatin; Cilastati | 1999 |
Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Clavulanic Acids; Drug Combination | 1990 |
Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Female; Fran | 1990 |
[Efficacy of injectable ofloxacin in treating septicemia. Multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Gram-Negative Bacteria; Humans; Injections, Intr | 1989 |
28 other studies available for ofloxacin and Sepsis
| Article | Year |
|---|---|
Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin.
Topics: Abscess; Bacterial Toxins; Exotoxins; Humans; Leukocidins; Magnetic Resonance Imaging; Male; Methici | 2014 |
Sepsis caused by Elizabethkingia miricola successfully treated with tigecycline and levofloxacin.
Topics: Anti-Bacterial Agents; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxa | 2008 |
Tako-tsubo cardiomyopathy observed in a patient with sepsis and transient hyperthyroidism.
Topics: Amlodipine; Anti-Bacterial Agents; Antihypertensive Agents; Antithyroid Agents; Aspirin; Echocardiog | 2009 |
Chryseobacterium septicemia in a renal allograft recipient.
Topics: Bronchopneumonia; Chryseobacterium; Flavobacteriaceae Infections; Humans; Kidney Transplantation; Ma | 2010 |
Tsukamurella tyrosinosolvens and Rhizobium radiobacter sepsis presenting with septic pulmonary emboli.
Topics: Actinomycetales; Actinomycetales Infections; Aged; Agrobacterium tumefaciens; Anti-Bacterial Agents; | 2011 |
Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Drug Resistance, Bacterial; Flu | 2011 |
Editorial comment.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy, Needle; Drug Resistance, Bacterial; Fluoroqui | 2011 |
Prospective study of antibiotic prophylaxis for prostate biopsy involving >1100 men.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy; Cephalosporins; Drug Resistance, Bacter | 2012 |
[Digital purpura revealing septicaemical rat-bite fever].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Arthritis, Infectious; Diagnosis, Differential; | 2002 |
Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.
Topics: Aged; Anti-Infective Agents; Area Under Curve; Blood Proteins; Drug Delivery Systems; Female; Humans | 2003 |
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Transport, Active; Car | 2003 |
A rare cause of pericarditis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; HIV Infections; HIV-1; Humans; | 2003 |
Short Communication: Yersinia pseudotuberculosis septicemia in an HIV-infected patient failed HAART.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Ceftriaxone; Dr | 2004 |
Effects of G-CSF and antibiotic prophylaxis in a 2 x 2 factorial design on outcome in septic rats.
Topics: Abdomen; Animals; Antibiotic Prophylaxis; Cefuroxime; Clinical Trials as Topic; Disease Models, Anim | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN | 2005 |
Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Disease Models, Animal; Endotoxins; Humans; I | 2005 |
An unusual cause of sepsis during pregnancy: recognizing infection with chlamydophila abortus.
Topics: Abortion, Spontaneous; Adult; Animals; Chlamydophila psittaci; Female; Goat Diseases; Goats; Humans; | 2005 |
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Outer Membrane Proteins; Disease Models, | 2006 |
Diaphragm paralysis in children after cardiac surgery.
Topics: Anti-Bacterial Agents; Cardiac Surgical Procedures; Cefazolin; Diaphragm; Female; Heart Defects, Con | 2007 |
Paratyphoid sepsis.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Bottle Feeding; Breast Feeding; Cesarean Section; Female; Fo | 2007 |
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Anuria; Aza Compounds; Critical Care; Criti | 2006 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998.
Topics: Anti-Bacterial Agents; Bacterial Capsules; Cefotaxime; Chloramphenicol; Clindamycin; Drug Resistance | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; L | 2000 |
Short and long courses of ofloxacin therapy of Klebsiella pneumoniae sepsis following irradiation.
Topics: Animals; Cobalt Radioisotopes; Drug Administration Schedule; Female; Ileum; Immunocompromised Host; | 1992 |
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe | 1991 |
Oral ofloxacin therapy of Pseudomonas aeruginosa sepsis in mice after irradiation.
Topics: Animals; Cobalt Radioisotopes; Female; Ileum; Liver; Mice; Mice, Inbred Strains; Microbial Sensitivi | 1990 |
[Development of Aeromonas hydrophila septicemia in a young healthy woman].
Topics: Adult; Aeromonas; Bacterial Infections; Drug Therapy, Combination; Female; Humans; Moxalactam; Oflox | 1988 |